CircGLIS3 promotes the progression of prostate cancer by regulating the p53 signaling pathway through the miR‐661/MDM2 axis; knocking down this pathway may improve the response of prostate cancer cells to enzalutamide.345. This evidence concerns the gene TP53 and prostate carcinoma.